Becton, Dickinson and Company (BDX) $154.88
Becton Dickinson is currently trapped in a technical tug-of-war between a recovering SMA50 and a heavy Volume Profile Point of Control at $155.
52-wk High $187.35
📌 Investment Snapshot
- Price of $154.88 sits 17.3% below 52-week highs with a 26.3x P/E ratio.
- Latest Q2 revenue hit $4.71B with a surprising EPS loss of -$1.11.
- Institutional backing remains massive with Blackrock and Vanguard holding 44M+ shares.
- Analyst consensus points to $176.92, implying a 14.2% recovery potential.
⏳ WAIT
BDX is showing signs of a trend reversal as it reclaims its SMA50, yet it remains capped by the 200-day moving average. The upcoming August 6 earnings report introduces significant binary risk following a volatile previous quarter.
| 📍 Entry Zone | $147.20 or below | 🛑 Stop-Loss | $139.50 |
| 📋 Adjust If | August earnings confirm a return to positive EPS guidance. | ||
The Investment Case — Why Now?
The narrative around Becton Dickinson has shifted over the last 90 days from steady dividend aristocrat to a turnaround play following the March EPS miss. While the 6.4% monthly return suggests buyers are returning, the stock is still digesting the heavy selling pressure seen in early 2026.
The primary risk remains the margin compression evidenced by the recent quarterly loss, which could derail the 2.79% dividend safety if not corrected. With the 10Y Treasury at 4.55%, BDX must prove its growth story to justify its premium valuation over lower-risk fixed income.
Can BDX justify a 26x multiple if the next earnings report fails to show a clear path back to $2.00+ EPS?
🤔 Can BDX justify a 26x multiple if the next earnings report fails to show a clear path back to $2.00+ EPS?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Instruments |
| Dividend Yield | 2.79% |
| Short Interest | 4.6% |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $149.69
The stock recently cleared its SMA50 ($147.86), but the SMA200 at $152.72 is acting as a stiff ceiling for the current rally. A decisive daily close above $155 is required to shift the long-term bias from bearish to bullish.
RSI at 59.1 confirms that while momentum is positive, we are no longer in the ‘easy money’ oversold zone. The ADX of 18.3 signals a weak trend, suggesting the current move may be a choppy consolidation rather than a vertical breakout.
Price is currently hovering right at the Volume Profile POC of $155.03, a level where high-volume nodes often stall price action. This ‘fair value’ area typically requires a significant fundamental catalyst to breach.
We note a bullish divergence in the liquidity sweeps, with the recent $149.69 buy-side sweep suggesting institutional accumulation at lower levels. However, the unfilled Bullish FVG down at $145.59 remains a magnetic target if earnings disappoint.
Historically, when BDX trades between its 50-day and 200-day MAs with a neutral ADX, it tends to range-trade for 3-5 weeks. Expect sideways action until the August 6 volatility event provides a directional cue.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| BDX | Becton Dickinson | 26.3x |
| ABT | Abbott Labs | 24.5x |
| TMO | Thermo Fisher | 31.2x |
| SPY | S&P 500 Avg | 21.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| 2026-03-31 | $4.71B | -$1.11 | -14% |
| 2025-12-31 | $5.25B | $1.34 | +5% |
| 2025-09-30 | $5.89B | N/A | +8% |
| 2025-06-30 | $5.51B | $2.00 | +6% |
BDX generated $0.5B in Free Cash Flow last quarter, supporting $0.2B in share buybacks despite the GAAP EPS loss.
The massive EPS miss in March 2026 was a shock to the system, largely attributed to one-time charges and supply chain realignments. Markets are now hyper-focused on the August 6 report to see if the $2.00 EPS run-rate can be reclaimed.
🚀 Growth Drivers — What Moves the Stock
- GLP-1 Ancillary Demand 🟢 Upside Surprise — Increased injectable drug use is driving higher demand for BD’s specialized delivery systems and needles.
- MedTech Automation 🟡 Priced In — Expansion into pharmacy automation and robotic lab systems is offsetting slower growth in traditional consumables.
🤔 Will the surge in GLP-1 drug delivery be enough to offset the margin pressure in BD’s core diagnostics segment?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 26,153 |
| Vanguard Capital Management | 18,490 |
| State Street Corp | 13,822 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| POLEN THOMAS E JR | CEO | 2026-06-01 | Purchase | 20,209 |
| MUHSIN BILAL | Officer | 2026-07-01 | Purchase | 14,342 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 4.6% | 3.9 |
⚠ Key Risk Factors
~$4B cap impact
Valuation cap
🎯 Guidance & Wall Street View
Management has been quiet following the Q1 restructuring, but analysts expect a return to mid-single-digit revenue growth by year-end.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $225.00 | $176.92 | $150.00 | 12 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | $185 | 2026-07-06 | Maintained |
| Wells Fargo | Equal-Weight | $160 | 2026-05-08 | Maintained |
While the consensus is a ‘Buy’, recent ratings from Piper Sandler and TD Cowen suggest a more cautious ‘Hold/Neutral’ stance among top-tier firms.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- CEO insider buying signals confidence in a H2 2026 recovery.
- Successful integration of recent acquisitions boosts margins.
📊 Base Case
BDX continues to trade within its $145-$160 range as it works through supply chain headwinds.
🐻 Bear Case
- August earnings show another EPS miss, breaking support at $140.
- Rising interest rates force a further de-rating of MedTech multiples.
🎯 Investor Action Plan — By Profile
Avoid entry here as RSI nears 60 and price hits the $155 POC. Look for a pullback to the $147.20 FVG zone for a better risk/reward setup.
Maintain current positions but do not add until the August 6 earnings report clears the air on the recent EPS volatility.
Wait for a confirmed Golden Cross (SMA50 over SMA200) or a price drop toward the $140 level to lock in a 3%+ yield.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: When is the next BDX earnings date?
Becton Dickinson is scheduled to report its next quarterly results on August 6, 2026.
Q: Is the BDX dividend safe?
With a 2.79% yield and $0.5B in quarterly free cash flow, the dividend appears safe, though the recent GAAP loss bears watching.
Q: What is the key technical level to watch?
The $155 level is the critical Point of Control; a breakout above this with high volume would signal a new bullish phase.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to verify if this analysis still holds?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. BDX involves risks related to healthcare regulation and global supply chains.
All active positions and their real-time performance are tracked on our Investment Log.
#BDX #MedTech #StockMarket #Investing #HealthcareStocks #TechnicalAnalysis